TABLE III.
Logistical regression analysis of risk factors in relation to immune-related adverse eventsa
| Variable | Comparator | Pts (n) | Immune-related adverse events | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Yes [n (%)] | No [n (%)] | Unadjusted analysis | Adjusted analysis | p Value | |||||
|
|
|
||||||||
| OR | 95% CI | OR | 95% CI | ||||||
| Sex | Men | 48 | 30 (63) | 18 (38) | 0.35 | 0.14 to 0.89 | 0.094 | 0.021 to 0.415 | 0.002 |
| Women | 30 | 11(37) | 19 (63) | Reference | Reference | ||||
|
| |||||||||
| History of autoimmune disease | No | 66 | 33 (50) | 33 (50) | 2.00 | 0.549 to 7.29 | 9.55 | 1.34 to 68.22 | 0.025 |
| Yes | 12 | 8 (67) | 4(33) | Reference | Reference | ||||
|
| |||||||||
| Corticosteroids before immunotherapy | No | 54 | 36 (63) | 20 (37) | 0.242 | 0.086 to 0.685 | 0.143 | 0.036 to 0.562 | 0.005 |
| Yes | 24 | 7 (29) | 17 (71) | Reference | Reference | ||||
|
| |||||||||
| Immunotherapy agent | PD-1 | 53 | 24 (45) | 29 (55) | 2.57 | 0.95 to 6.99 | 6.25 | 1.61 to 24.25 | 0.008 |
| Anti–CTLA-4 | 25 | 17 (68) | 8 (32) | Reference | Reference | ||||
|
| |||||||||
| Kidney function | Stages 1–2 | 63 | 29 (47) | 34 (54) | 4.69 | 1.21 to 18.25 | 10.66 | 2.41 to 47.12 | 0.025 |
| Stages 3–4 | 15 | 12 (80) | 3 (20) | Reference | Reference | ||||
a
Hosmer–Lemeshow test for goodness of fit: 0.979.
Pts = patients; OR = odds ratio; CI = confidence interval.